More than 90 federal grants totaling $92 million were awarded to USC researchers in 2020, underscoring the university’s status as one of the nation’s leading research centers as we acknowledge World Alzheimer’s Day 2021.
Fine particle pollution may be one reason why Black women have double the risk of developing Alzheimer’s than white women, new research from the Keck School of Medicine of USC suggests.
Experts from the USC Leonard Davis School of Gerontology share what they’ve learned from years of studying Alzheimer’s disease.
A newly approved yet controversial drug, in particular, brings both hope and challenges for patients and clinicians.
A new USC study may have unlocked therapy options to slow cognitive impairment in people with the APOE4 gene, which has long been associated with Alzheimer’s disease.
A grant from the National Institutes of Health will allow the Han Research Lab to study the link between financial decision-making and Alzheimer’s disease.
You might find a hangover cure, protection against Alzheimer’s and much more in nature’s bounty.
Using MRIs and machine learning, USC researchers mapped comparable degenerative changes in both gray and white matter of the brain.
New disease-modifying treatments would help Medicaid avoid paying $186 billion from 2021 to 2040, a new USC study has found.
High levels of fine particle pollution are associated with brain shrinkage patterns common in Alzheimer’s disease, a USC study finds.
A $17.8 million grant from the National Institutes of Health will fund an AI-powered study of genetic, imaging and cognitive data collected from Alzheimer’s patients.
Keck Medicine of USC is now enrolling individuals in a phase 3 clinical trial that will implant electrodes into subjects’ brains to potentially stop the progression of the disease.
A USC research team has found strong evidence that keeping blood vessels healthy can help prevent cognitive decline.
The inaugural class of the IMPACT-AD program, which is co-directed by a USC professor, will educate 35 professionals at various career stages on conducting more diverse clinical trials.
USC’s Center for Advancing Sociodemographic and Economic Study of Alzheimer’s Disease will explore the enormous costs of Alzheimer’s and related dementias.
Death certificate data appear to underestimate the true mortality burden of dementia, Alzheimer’s disease and other cognitive impairment, according to a USC-led study.
“It’s never too early or too late to take action,” says Lon Schneider of the Keck School of Medicine of USC, co-director of the USC Alzheimer Disease Research Center’s clinical core.
USC research shows how several major countries could prepare their health systems to ensure patients can get Alzheimer’s treatments once they hit the market.
Although scientists have long known APOE4 is a leading risk factor for Alzheimer’s disease, they were unsure how exactly it drives a decline in memory. USC researchers now believe they have an answer.
In a first, a USC study has shown that drugs already being used for blood pressure and cholesterol control could provide benefits for Alzheimer’s and other dementias.
Keck School of Medicine of USC is launching a large clinical trial that targets amyloid plaques in the brain. The goal: to see whether a drug can clear or slow this plaque in people who have early Alzheimer’s or who appear clinically normal.
María Aranda will bring her expertise as a researcher and a social worker to Gov. Gavin Newsom’s Task Force on Alzheimer’s Prevention and Preparedness.
Funding from the National Institutes of Health — the world’s largest public funder of biomedical research — was $68 million last year, a substantial increase from $13 million in 2015.
November is Alzheimer’s Awareness Month, and USC scientists are researching healthy lifestyle choices and certain drugs that might reduce the risk of developing the disease.